NuvOx Pharma LLC Announces Receipt of Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medical Products

NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced that it has received a Qualified Person’s Declaration Equivalence to UK / EU GMP for Investigational Medicinal Products Manufactured outside of EU (in Third Countries) . This... - September 21, 2024 - NuvOx Therapeutics

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics Announce Collaboration to Develop Breakthrough Antibody Therapeutics for Neurological Disorders

Sama Therapeutics and Quine Biologics have partnered to develop an innovative therapy for neurological disorders, combining AI-driven platforms and advanced antibody engineering. The collaboration focuses on biologics that precisely target the central nervous system, minimizing side effects. By integrating Sama's generative AI with Quine's antibody design expertise, the project addresses unmet medical needs and advances treatments for conditions like Alzheimer’s and multiple sclerosis. - September 13, 2024 - Quine Biologics, Inc.

Microvascular Therapeutics Announce Completion of Phase 2 Study Enrollment for MVT-100

Microvascular Therapeutics (MVT), a pioneering healthcare research and development company, is pleased to announce the completion of enrollment in MVT’s Phase 2 program using its microbubble product, MVT-100, for endocardial border delineation. This study, An Ascending Dose Comparison of... - September 13, 2024 - Microvascular Therapeutics, Inc.

Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients

Huntington Study Group and HD Genetics Collaborate to Better Serve HD Gene Positive Patients

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce a strategic partnership with HD Genetics to assist patients who have tested positive for Huntington’s disease (HD) learn about and enroll in research studies. There remains a... - September 05, 2024 - Huntington Study Group

Huntington Study Group Announces New CEO

Huntington Study Group Announces New CEO

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce that Daniel Claassen, MD, MS, an internationally recognized Huntington’s Disease neurologist and researcher has accepted the role as the organization’s Chief Executive... - August 20, 2024 - Huntington Study Group

Guides Collective Steps in Where Traditional Therapies have Failed with a Concierge Service to Match Seekers with Psychedelic Guides

Guides Collective Steps in Where Traditional Therapies have Failed with a Concierge Service to Match Seekers with Psychedelic Guides

Guides Collective launches psychedelic concierge service poised to become the "BetterHelp" of the psychedelic space. With over 600+ qualified psychedelic guides in their network, they work with you to find a psychedelic modality catered to a persons specific needs and desired outcome. - August 14, 2024 - Guides Collective

Parvus Therapeutics Announces Leadership Appointments to Support Development from Preclinical Into Clinical

New Positions Enhance Parvus Capability to Execute the Translation of Multiple Drug Candidates into the Clinic. - August 06, 2024 - Parvus Therapeutics U.S., Inc.

Parvus Therapeutics Has Received Orphan Drug Designation for Primary Biliary Cholangitis and Human Research Ethics Committee Approval to Begin Clinical Testing

Parvus Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to PVT201 for the treatment of Primary Biliary Cholangitis (PBC) and PVT201 has obtained Australian Human Research Ethics Committee (HREC) approval to initiate a first-in-human... - July 29, 2024 - Parvus Therapeutics U.S., Inc.

Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment

Leap Years®: Supports Age-Related Cognitive Decline in Dogs and Quality Time Together with Owners Through NAD+ Enrichment

Animal Biosciences Announces Peer-Reviewed Publication of a Clinical Trial to Evaluate the Slowing of Age-Related Signs in Dogs. After five years of development, clinical results are published regarding senior dog aging in a rigorous, placebo-controlled trial performed at a North Carolina State University College of Veterinary Medicine. - July 23, 2024 - Leap Years

MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy

MC4R Agonist Drug Candidates Demonstrate Potential to Transform GLP1 Obesity Therapy

Courage Therapeutics announced new evidence of synergy between MC4R agonists and GLP1RA drugs in a paper published in the Journal of Clinical Investigation led by co-founder Dr. Roger Cone. The company has completed a drug discovery campaign to invent a best in class portfolio of MC4R agonists for obesity in order to leverage the synergy. Potential combinations with drugs such as Ozempic and Mounjaro could improve side effects such as nausea and GI discomfort while driving increased weight loss. - July 16, 2024 - Courage Therapeutics

Huntington Study Group Announces Launch of LEAD-HD Observational Study

Huntington Study Group Announces Launch of LEAD-HD Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) today announce the release of their newest Patient Reported Outcomes (PRO) study, LEAD-HD. This observational study was developed collaboratively with the University of Rochester Center for Health +... - July 15, 2024 - Huntington Study Group

NuvOx Pharma LLC Announces Authorization of ARDS Trial from Health Canada

NuvOx Pharma LLC (“NuvOx”) announced that it has received authorization from Health Canada for its EXTEND: novEl oXygen ThErapeutic NanO2 for mild respiratory distress in Phase Ib and ARDS in Phase II Trials. Evan Unger, MD, CEO of NuvOx, said, “Acute Respiratory Distress... - July 12, 2024 - NuvOx Therapeutics

Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.

Huntington Study Group Launches Project AWARE 2.0 Observational Study

Huntington Study Group Launches Project AWARE 2.0 Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group

FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology

The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer

Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.

Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety

Creative Diagnostics has announced the launch of Aflatoxin Test Reagents to detect harmful mycotoxins in various food products. - February 04, 2024 - Creative Diagnostics

Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy

Creative Diagnostics has announced its extensive portfolio of AAV Reagent Solutions to support researchers. - February 04, 2024 - Creative Diagnostics

Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens

Creative Diagnostics is pleased to announce the launch of its Serum Plate Agglutination Test. - February 04, 2024 - Creative Diagnostics

Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report

New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC

Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues

Creative Diagnostics has announced the launch of its new Robenidine Test Reagents for the detection of robenidine residues. - January 26, 2024 - Creative Diagnostics

Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness

Creative Diagnostics has announced new Minimum Doubling Time (MDT) services to measure the effectiveness of antibacterial compounds. - January 26, 2024 - Creative Diagnostics

Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research

Creative Diagnostics has announced P53 and TP53 antibodies and solutions to support cancer research. - January 26, 2024 - Creative Diagnostics

Huntington Study Group Announces 2024 Annual Meeting

Huntington Study Group Announces 2024 Annual Meeting

The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group

Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report

IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC

NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” - January 14, 2024 - NuvOx Therapeutics

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group

Creative Diagnostics Announces New MBC Assay for Antibacterial Testing

Creative Diagnostics has announced the launch of its new Minimum Bactericidal Concentration (MBC) Assay for antibacterial testing. - December 13, 2023 - Creative Diagnostics

Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications

Creative Diagnostics has launched a portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents for researchers. - December 13, 2023 - Creative Diagnostics

Creative Diagnostics Announces New Test Reagents for Dapsone

Creative Diagnostics has announced the launch of a range of new reagents for the analysis of Dapsone in food. - December 13, 2023 - Creative Diagnostics

Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program

Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.

Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction

Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.

FF Biotherapeutics Announces Search for Angel Investment to Revolutionize Immunotherapy and Vaccine Development

FF Biotherapeutics Announces Search for Angel Investment to Revolutionize Immunotherapy and Vaccine Development

FF Biotherapeutics, a pioneering biotech startup at the forefront of immunotherapy and vaccine development, today announced its active pursuit of Angel investment. This critical funding round aims to propel the development of its groundbreaking Synthetic Standardized Convalescent Plasma (SSCP) and... - November 29, 2023 - FF Biotherapeutics

Huntington Study Group® Holds 30th Annual Meeting

Huntington Study Group® Holds 30th Annual Meeting

The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023 - Huntington Study Group

Creative Diagnostics Launches Carbamazepine Test Reagents

Creative Diagnostics has announced the release of its new line of Carbamazepine Test Reagents. - November 04, 2023 - Creative Diagnostics

Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services

Creative Diagnostics has recently launched a series of new Minimum Inhibitory Concentration (MIC) assay services for researchers. - November 04, 2023 - Creative Diagnostics

Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research

Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has launched a range of antibodies, antigens and kits against CLDN6 to support researchers worldwide in preclinical and clinical safety/efficacy testing. CLDN6 may be involved in the development and... - November 04, 2023 - Creative Diagnostics

Microvascular Therapeutics Receives $3.98M Award from Department of Defense for Its Cardiovascular Product

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief... - October 18, 2023 - Microvascular Therapeutics, Inc.

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory®  Platform Reaches the Unreachable

Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable

The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group

Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development

Creative Diagnostics has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of NALFIA. - October 15, 2023 - Creative Diagnostics

Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications

Creative Diagnostics has announced the release of its new line of Azaperone Test Reagents. - October 15, 2023 - Creative Diagnostics

Creative Diagnostics Launches Checkerboard Assay Services

Creative Diagnostics has recently announced the launch of its new Checkerboard Assay services to support researchers. - October 15, 2023 - Creative Diagnostics

NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School

NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. - October 11, 2023 - NuvOx Therapeutics

Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions

Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company

Press Releases 1 - 50 of 1,356